psoralen/inflammation

The onset and progression of alopecia areata are unpredictable. Significant variations in the clinical presentation of alopecia areata have been observed, ranging from small, well-circumscribed patches of hair loss to a complete absence of body and scalp hair. Although many patients improve

Atopic dermatitis (AD), an itchy eczema with a chronic relapsing course, is the most common clinical manifestation of atopy in the first years of life. On the basis of the available knowledge, AD is produced by an alteration of the skin barrier which triggers an inflammatory reaction. Such reaction

Introduction As numerous studies have identified TNF-α, TH-17 and IL-17 as particularly major roles governing the inflammatory cascade in psoriasis, target therapies, including TNF-α and TH-17 antagonists, have represented major breakthrough in the treatment of psoriasis. It is well known that TNF-α

Atopic dermatitis (AD) is a very common skin disorder that is characterized by pruritic inflammatory skin lesions, with patients usually having an individual or family history of atopic diseases in their background (e.g., allergic asthma and rhinitis). Defective skin barrier, immunological

The occurrence of acute or chronic graft-versus-host disease (GVHD) and its prevention/treatment induce further immunologic compromise. Graft-versus-host disease (GvHD) accounts for significant morbidity and mortality in recipients of allogeneic bone marrow transplants (BMT) or peripheral blood stem

Psoriasis is an inflammatory skin disease affecting approximately 2% of the population, and approximately one-third of patients experience generalized psoriasis ( ). Current treatment options include topical medications, ultraviolet B and oral psoralen with ultraviolet A phototherapy, biologic

Hand dermatitis, also called fu kuei shou, is a skin condition in which the hands develop a rash and become red, dry, cracked, and inflamed. This is a very common occuring in about 10% of women and 4% of men. The condition can eventually cause pain on contact with even simple solutions such as

Investigator driven study Immunopharmacological Effects of Rituximab in Atopic Dermatitis Investigators 1. Prof. Dr. Hans-Uwe Simon (Dept. of Pharmacology, University of Bern, Switzerland) 2. Dr. Dagmar Simon, Prof. Dr. Lasse R. Braathen (Dept. of Dermatology, University of Bern,